Capecitabine in combination with panitumumab is not the treatment of choice in older patients with metastatic colorectal cancer

J Geriatr Oncol. 2022 Jan;13(1):114-115. doi: 10.1016/j.jgo.2021.09.001. Epub 2021 Sep 8.

¹ Department of Oncology, Odense University Hospital, J.B. Winsløws Vej 4., 5000, Odense C, Denmark; Department of Clinical Research, University of Southern Denmark, J.B. Winsløws Vej 4., 5000, Odense C, Denmark; Academy of Geriatric Cancer Research (AgeCare), Denmark. Electronic address: [email protected].
² Department of Oncology, Odense University Hospital, J.B. Winsløws Vej 4., 5000, Odense C, Denmark; Department of Clinical Research, University of Southern Denmark, J.B. Winsløws Vej 4., 5000, Odense C, Denmark; Academy of Geriatric Cancer Research (AgeCare), Denmark.

No abstract available

Keywords: Capecitabine; EGFR-inhibitor; Metastatic colorectal cancer; Older patients; Panitumumab.

Publication types